Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
4 raisons identifiées
Auteur de référence en rhumatologie
36 articles scientifiques publiés — un praticien à la pointe de la recherche
Cabinet de groupe — continuité de soins
Plusieurs praticiens dans le même cabinet — un confrère peut prendre le relais en cas d'absence
Disponibilité géographique
6 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
126.7 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
SELAS IMALLIANCE HDF
9 AVENUE DES DENTELLIERES, 59300 VALENCIENNES
SELAS IMALLIANCE HDF
108 AVENUE DE LA LIBERATION, 59310 ORCHIES
SELAS IMALLIANCE HDF
CENTRE HOSPITALIER 25 B AVENUE JEAN JAURES, 59220 DENAIN
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
SELAS IMALLIANCE HDF
CLINIIQUE DU PARC 48 B RUE HENRI BARBUSSE, 59880 ST SAULVE
SELAS IMALLIANCE HDF
8-10 AVENUE VAUBAN, 59300 VALENCIENNES
SELAS IMALLIANCE HDF
CENTRE HOSPITALIER AVENUE DESANDROUIN, 59300 VALENCIENNES
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Clinical psychology review · 2023
Frontiers in medicine · 2021
Background: Protease inhibitors have been considered as possible therapeutic agents for COVID-19 patients.Objectives: To describe the association between lopinavir/ritonavir (LPV/r) or darunavir/cobicistat (DRV/c) use and in-hospital mortality in COVID-19 patients.Study Design: Multicenter observational study of COVID-19 patients admitted in 33 Italian hospitals. Medications, preexisting conditions, clinical measures, and outcomes were extracted from medical records. Patients were retrospectively divided in three groups, according to use of LPV/r, DRV/c or none of them. Primary outcome in a time-to event analysis was death. We used Cox proportional-hazards models with inverse probability of treatment weighting by multinomial propensity scores.Results: Out of 3,451 patients, 33.3% LPV/r and 13.9% received DRV/c. Patients receiving LPV/r or DRV/c were more likely younger, men, had higher C-reactive protein levels while less likely had hypertension, cardiovascular, pulmonary or kidney disease. After adjustment for propensity scores, LPV/r use was not associated with mortality (HR = 0.94, 95% CI 0.78 to 1.13), whereas treatment with DRV/c was associated with a higher death risk (HR = 1.89, 1.53 to 2.34, E-value = 2.43). This increased risk was more marked in women, in elderly, in patients with higher severity of COVID-19 and in patients receiving other COVID-19 drugs.Conclusions: In a large cohort of Italian patients hospitalized for COVID-19 in a real-life setting, the use of LPV/r treatment did not change death rate, while DRV/c was associated with increased mortality. Within the limits of an observational study, these data do not support the use of LPV/r or DRV/c in COVID-19 patients.
Stem cells translational medicine · 2021
Abstract Buerger's disease or thromboangiitis obliterans is a type of obstructive vascular diseases categorized as vasculitis and usually present in 95% of young smoker men. The main pathogenetic mechanism is interplay between immune system and inflammation. Earlier our phase II study has shown that Stempeucel is safe when injected at 2 million cells/kg body weight by virtue of its anti-inflammatory, immunomodulatory, and angiogenetic properties. The present study was conducted to further assess the safety and efficacy of Stempeucel in critical limb ischemia due to Buerger's disease after obtaining approval from Indian FDA based on the data generated in the phase II study. This is an open label, multicenteric phase IV PMS study conducted across India with experienced vascular surgeons. Fifty patients of critical limb ischemia due to Buerger's disease with Rutherford III-5 or III-6 were included in the study and each individual received a dose of 2 million cells/kg body weight of Stempeucel in the calf muscles and around the ulcer. These patients were evaluated over 12 months from drug administration. The present study showed the continued long term efficacy over a period of 12 months follow up in these patients corroborating the result obtained in the previous phase II studies. There was significant improvement in rest pain, ankle systolic pressure, and ankle brachial pressure index with accelerated ulcer healing. In conclusion, the present study shows that the intramuscular administration of Stempeucel continues to be safe, tolerable, and effective alternative treatment in patients with Buerger's disease.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
The Journal of international medical research · 2026 · Journal Article
Been Sayeed SKJ, M M, Mahmud R, Rahman S, et al.
Bioinformation · 2025 · Journal Article
G N, M SSL, V S, K S, et al.
Brain, behavior, & immunity - health · 2023 · Journal Article
Graïc JM, Finos L, Vadori V, Cozzi B, et al.
PLoS neglected tropical diseases · 2023 · Journal Article
Guttapadu R, Prakash N, M A, Chatterjee R, et al.
medRxiv : the preprint server for health sciences · 2022 · Preprint
Ghosh P, Niesen MJM, Pawlowski C, Bandi H, et al.
Frontiers in medicine · 2021 · Journal Article
Di Castelnuovo A, Costanzo S, Antinori A, Berselli N, et al.
Osteoarthritis and cartilage open · 2021 · Journal Article
A D, A T, T J, O R, et al.
Current computer-aided drug design · 2020 · Journal Article
M S, B P, Swaminathan P
Drug design, development and therapy · 2019 · Journal Article
Kameoka Y, F K, M K
International journal of biological macromolecules · 2018 · Journal Article
S S, R S, V U, B A, et al.
Journal of pediatric urology · 2025 · Journal Article
Taghizadeh AK, Clothier J, Page A, Manuele R, et al.
Clinical psychology review · 2023 · Meta-Analysis
Manuele SJ, Yap MBH, Lin SC, Pozzi E, et al.
Journal of pediatric urology · 2023 · Journal Article
Bhandarkar K, Giannettoni A, Mishra P, Paul A, et al.
Clinical rheumatology · 2025 · Journal Article
A K, M EA, M H, H A, et al.
Rheumatology and immunology research · 2024 · Journal Article
Datta D, Khatun M, Bankura B, Sarkar M, et al.
Cureus · 2024 · Case Reports
Surapaneni D, Dasi SC, Sam N, M J
Journal of healthcare engineering · 2021 · Journal Article
Di Castelnuovo A, Gialluisi A, Antinori A, Berselli N, et al.
European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · 2026 · Journal Article
Niccolò S, Manuele MG, Barbara B, Paolo M, et al.
JMIR research protocols · 2025 · Journal Article
M A, Ahmad A, A A, Raj LS, et al.
Physiotherapy · 2026 · Letter
Rashid FA, M RP
Journal of orthopaedic case reports · 2018 · Case Reports
Shankar K, M S, Raizada P, Jain R
Clinical psychology review · 2023 · Meta-Analysis
Manuele SJ, Yap MBH, Lin SC, Pozzi E, et al.
Archives of gerontology and geriatrics · 2021 · Journal Article
M R, M A, H B, M O
JACC. Case reports · 2024 · Case Reports
Kharge JL, M UK, M L J, Newaskar AA, et al.
Stem cells translational medicine · 2021 · Clinical Trial, Phase IV
Gupta PK, Dutta S, Kala S, Nekkanti M, et al.
Cureus · 2023 · Journal Article
M D, Kumar J, Ramalingam K
Journal of clinical medicine · 2020 · Journal Article
Scicali R, Russo GI, Di Mauro M, Manuele F, et al.
Journal of neurosciences in rural practice · 2020 · Journal Article
Vijayan BV, Nair VCP, M G
Clinical rheumatology · 2025 · Journal Article
Mohan A, Mohan A, Ramachandran A, Pulinilkunnathil JG, et al.
The Journal of the Association of Physicians of India · 2022 · Journal Article
Murugesan H, Cs G, Nasreen HS, Santhanam S, et al.
BMJ case reports · 2025 · Journal Article
Pathrot D, Nachappa AA, Mannual S, M SK
Indian journal of dermatology, venereology and leprology · 2023 · Letter
Rao AG, M N, Ch S, Jhawar J
Radiology case reports · 2023 · Case Reports
Lee ZR, Lai YK, M L, Khor LY, et al.
Journal of orthopaedic case reports · 2018 · Case Reports
Shankar K, M S, Raizada P, Jain R
Cureus · 2025 · Journal Article
Nallaperumal S, V P, M C V, Pusapati LCV, et al.
Clinical psychology review · 2023 · Meta-Analysis
Manuele SJ, Yap MBH, Lin SC, Pozzi E, et al.
Cureus · 2022 · Case Reports
Chandra MS, G A M, M RK
Surgery journal (New York, N.Y.) · 2019 · Journal Article
Chan CM, Cisneros EF, M T
Cureus · 2024 · Case Reports
Mohan A, Kuriakose SM, James L, G BT, et al.